Frank J Gonzalez Selected Research

Cytoplasmic and Nuclear Receptors (Nuclear Receptors)

5/2022	Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity.
1/2022	HNF4A modulates glucocorticoid action in the liver.
1/2019	Pregnane X Receptor Regulates Liver Size and Liver Cell Fate by Yes-Associated Protein Activation in Mice.
1/2019	Keratin 23 Is a Peroxisome Proliferator-Activated Receptor Alpha-Dependent, MYC-Amplified Oncogene That Promotes Hepatocyte Proliferation.
1/2019	Regulatory mechanisms mediated by peroxisome proliferator-activated receptor-β/δ in skin cancer.
11/2017	Targeting nuclear receptors for the treatment of fatty liver disease.
9/2016	ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy.
11/2015	Establishing the Role of PPARβ/δ in Carcinogenesis.
1/2015	Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
6/2014	Hepatic PPARγ and LXRα independently regulate lipid accumulation in the livers of genetically obese mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frank J Gonzalez Research Topics

Disease

93	Neoplasms (Cancer) 01/2022 - 05/2002
64	Carcinogenesis 01/2022 - 05/2002
59	Inflammation (Inflammations) 05/2022 - 09/2004
39	Obesity 06/2022 - 10/2003
30	Insulin Resistance 01/2021 - 10/2002
26	Hypoxia (Hypoxemia) 01/2021 - 10/2003
21	Non-alcoholic Fatty Liver Disease 06/2022 - 04/2011
21	Hypertension (High Blood Pressure) 11/2021 - 04/2005
21	Necrosis 01/2021 - 12/2004
20	Hepatocellular Carcinoma (Hepatoma) 10/2021 - 04/2002
20	Fatty Liver 01/2021 - 03/2003
20	Fibrosis (Cirrhosis) 01/2020 - 01/2004
19	Body Weight (Weight, Body) 01/2022 - 01/2004
19	Hepatomegaly 01/2022 - 06/2004
17	Liver Diseases (Liver Disease) 02/2022 - 05/2006
16	Colonic Neoplasms (Colon Cancer) 01/2019 - 10/2002
16	Cholestasis 01/2019 - 09/2003
14	Breast Neoplasms (Breast Cancer) 08/2020 - 09/2002
13	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 05/2004
13	Liver Neoplasms (Liver Cancer) 01/2022 - 06/2004
13	Colitis 11/2021 - 02/2007
13	Type 2 Diabetes Mellitus (MODY) 01/2021 - 10/2002
11	Metabolic Diseases (Metabolic Disease) 05/2022 - 02/2012
11	Dyslipidemias (Dyslipidemia) 02/2017 - 01/2006
9	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2021 - 02/2007
9	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 10/2010
8	Alcoholic Liver Diseases (Alcoholic Liver Disease) 02/2022 - 10/2004
8	Atherosclerosis 01/2021 - 12/2006
8	Glucose Intolerance 12/2018 - 10/2004
8	Hyperglycemia 12/2018 - 11/2004
8	Carcinoma (Carcinomatosis) 01/2018 - 05/2003
8	Proteinuria 01/2018 - 12/2009
7	Weight Gain 01/2020 - 01/2006
7	Hyperplasia 11/2018 - 06/2002
7	Starvation 12/2016 - 07/2002
7	Adenoma (Adenomas) 11/2010 - 03/2003
6	Hyperlipidemias (Hyperlipidemia) 01/2022 - 09/2003
6	Liver Cirrhosis (Hepatic Cirrhosis) 11/2020 - 01/2004
6	Hypertrophy 01/2020 - 04/2006
6	Skin Neoplasms (Skin Cancer) 01/2019 - 12/2008
6	Hepatitis 05/2017 - 06/2009
5	Mitochondrial Diseases (Mitochondrial Disease) 12/2021 - 04/2014

Drug/Important Bio-Agent (IBA)

63	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 05/2022 - 05/2004
45	LigandsIBA 01/2019 - 05/2002
41	PPAR alphaIBA 05/2022 - 04/2002
37	Bile Acids and Salts (Bile Acids)IBA 06/2022 - 09/2003
35	LipidsIBA 01/2022 - 11/2003
34	Proteins (Proteins, Gene)FDA Link 03/2021 - 06/2002
28	Fatty Acids (Saturated Fatty Acids)IBA 04/2022 - 07/2002
26	Pharmaceutical PreparationsIBA 11/2021 - 11/2003
25	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 05/2022 - 10/2003
25	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 08/2003
24	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 05/2022 - 09/2002
24	Transcription Factors (Transcription Factor)IBA 11/2020 - 10/2003
22	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2006
21	PPAR-betaIBA 03/2010 - 05/2004
20	Messenger RNA (mRNA)IBA 01/2019 - 05/2003
19	EnzymesIBA 05/2022 - 12/2002
19	PPAR gammaIBA 01/2017 - 05/2002
18	Insulin (Novolin)FDA Link 01/2022 - 08/2003
17	Angiotensin IIIBA 11/2021 - 10/2010
17	Triglycerides (Triacylglycerol)IBA 01/2019 - 08/2003
14	Fibric Acids (Fibrates)IBA 12/2018 - 06/2004
12	XenobioticsIBA 05/2022 - 12/2002
12	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 05/2019 - 01/2004
11	CeramidesIBA 06/2022 - 09/2014
11	CholesterolIBA 04/2022 - 05/2004
11	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 04/2008
11	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2022 - 12/2004
11	Pregnane X ReceptorIBA 11/2021 - 04/2007
10	Dextran SulfateIBA 01/2020 - 02/2008
9	Cytochrome P-450 CYP2E1 (CYP2E1)IBA 05/2022 - 01/2005
9	pirinixic acidIBA 01/2022 - 06/2007
9	CarcinogensIBA 12/2018 - 05/2002
9	(4- (((2- (3- fluoro- 4- (trifluoromethyl)phenyl)- 4- methyl- 1,3- thiazol- 5- yl)methyl)sulfanyl)- 2- methylphenoxy)acetic acidIBA 11/2011 - 11/2007
8	AzoxymethaneIBA 01/2019 - 10/2002
8	Fenofibrate (CiL)FDA LinkGeneric 01/2019 - 01/2008
8	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 09/2002
8	AntioxidantsIBA 01/2018 - 04/2003
8	Ethanol (Ethyl Alcohol)IBA 01/2017 - 10/2004
8	CytokinesIBA 09/2016 - 04/2003
7	Aryl Hydrocarbon Receptor Nuclear TranslocatorIBA 01/2021 - 11/2003
7	Multidrug Resistance-Associated ProteinsIBA 08/2020 - 12/2010
7	Rosiglitazone (Avandia)FDA Link 01/2019 - 03/2003
7	Choline (Choline Chloride)IBA 01/2018 - 11/2012
7	Methionine (L-Methionine)FDA Link 01/2018 - 07/2012
6	IronIBA 01/2022 - 10/2002
6	2- (2- (3,4- dihydroxy- 5- (hydroxymethyl)oxolan- 2- yl)- 1- methylcarbamimidamido)acetic acidIBA 01/2022 - 06/2014
6	Polychlorinated Dibenzodioxins (TCDD)IBA 12/2021 - 10/2003
6	Apolipoproteins E (ApoE)IBA 01/2021 - 12/2006
6	CollagenIBA 01/2020 - 01/2004
6	GlucuronidesIBA 01/2019 - 08/2013
6	Benzo(a)pyreneIBA 12/2018 - 04/2006
6	Gemfibrozil (Lopid)FDA LinkGeneric 02/2017 - 03/2009
6	Interleukin-6 (Interleukin 6)IBA 09/2016 - 11/2007
6	Phospholipids (Phosphatides)FDA LinkGeneric 01/2015 - 05/2004
6	anthraceneIBA 07/2014 - 02/2003
5	Therapeutic UsesIBA 06/2022 - 10/2012

Therapy/Procedure

26	Therapeutics 01/2022 - 10/2002
11	Chemoprevention 01/2019 - 09/2004